Identification of a promising drug candidate for the treatment of type 2 diabetes based on a P2Y1 receptor agonist

Journal of Medicinal Chemistry

Volumn 55, Issue 17, 2012, Pages 7623-7635

  Yelovitch, Shir ^a   Barr, Haim M ^b   Camden, Jean ^c   Weisman, Gary A ^c   Shai, Ela ^d   Varon, David ^d   Fischer, Bilha ^a  

^a BAR ILAN UNIVERSITY   (Israel)

^b BIOLINERX LTD   (Israel)

^c University of Missouri   (United States)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLTHIOADENOSINE 5' O (ALPHA BORANO)DIPHOSPHATE A; 2 METHYLTHIOADENOSINE 5' O (ALPHA BORANO)DIPHOSPHATE B; ACETYLSALICYLIC ACID; ALKALINE PHOSPHATASE; ANTIDIABETIC AGENT; CALCIUM; GLIBENCLAMIDE; GLUCOSE; PRASUGREL; PURINERGIC P2Y RECEPTOR AGONIST; PURINERGIC P2Y1 RECEPTOR; PURINERGIC P2Y1 RECEPTOR AGONIST; PURINERGIC P2Y2 RECEPTOR; PURINERGIC P2Y4 RECEPTOR; PURINERGIC P2Y6 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING TIME; CALCIUM CELL LEVEL; CONTROLLED STUDY; DRUG DEGRADATION; DRUG EFFICACY; DRUG STABILITY; DRUG SYNTHESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROLYSIS; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEOPHILICITY; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; THROMBOCYTE AGGREGATION;

ANIMALS; BLOOD GLUCOSE; CELL LINE, TUMOR; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MICE, INBRED ICR; MOLECULAR STRUCTURE; PURINERGIC P2Y RECEPTOR AGONISTS; RATS; RATS, WISTAR;

EID: 84866326616     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3006355     Document Type: Article

References (53)

1. Adeghate, E., Ed. Special Issue on Diabetes Mellitus and its Complications: From Molecular Biology to Clinical Medicine. In Archives of Physiology and Biochemistry; Swets & Zeitlinger B.V.: Lisse, Netherlands, 2001; Vol. 109, issue 3, p 96 ff.
2. Stefek, M., Ed. Advances in Molecular Mechanisms and Pharmacology of Diabetic Complications; Transworld Research Network: Kerala, India, 2010; p 341 ff.
3. Hegarty, B. D.; Turner, N.; Cooney, G. J.; Kraegen, E. W. Insulin resistance and fuel homeostasis: The role of AMP-activated protein kinase Acta Physiol. 2009, 196, 129-145
4. Scheen, A. J.; Castillo, M. J.; Lefebvre, P. J. Combination of oral antidiabetic drugs and insulin in the treatment of non-insulin-dependent diabetes Acta Clin. Belg. 1993, 48, 259-268 (Pubitemid 23300323)
5. U.K. Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 1998, 352, 837-853
6. Ishida, H. Mechanism of action of antidiabetic sulfonylureas Diabetes Front. 1999, 10, 99-104
7. Lebovitz, H. Oral Antidiabetic Agents; Lea and Febiger: Philadelphia, PA, 1994; pp 508-529.
8. Green, J. B.; Feinglos, M. N. Are sulfonylureas passe? Curr. Diabetes Rep. 2006, 6, 373-377
9. Selvin, E.; Bolen, S.; Yeh, H.-C.; Wiley, C.; Wilson Lisa, M.; Marinopoulos Spyridon, S.; Feldman, L.; Vassy, J.; Wilson, R.; Bass Eric, B.; Brancati Frederick, L. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review Arch. Intern. Med. 2008, 168, 2070-2080
10. Loubatieres-Mariani, M. M.; Chapal, J.; Lignon, F.; Valette, G. Structural specificity of nucleotides for insulin secretory action from the isolated perfused rat pancreas Eur. J. Pharmacol. 1979, 59, 277-286 (Pubitemid 10159517)
11. Chapal, J.; Loubatieres-Mariani, M. M. Effects of phosphate-modified adenine nucleotide analogs on insulin secretion from perfused rat pancreas Br. J. Pharmacol. 1981, 73, 105-110 (Pubitemid 11104767)
12. Hillaire-Buys, D.; Bertrand, G.; Chapal, J.; Puech, R.; Ribes, G.; Loubatieres-Mariani, M. M. Stimulation of insulin secretion and improvement of glucose tolerance in rat and dog by the P2y-purinoceptor agonist, adenosine-5′-O-(2-thiodiphosphate) Br. J. Pharmacol. 1993, 109, 183-187 (Pubitemid 23113820)
13. Fernandez-Alvarez, J.; Hillaire-Buys, D.; Loubatieres-Mariani, M. M.; Gomis, R.; Petit, P. P2 receptor agonists stimulate insulin release from human pancreatic islets Pancreas 2001, 22, 69-71 (Pubitemid 32046218)
14. Chapal, J.; Hillaire-Buys, D.; Bertrand, G.; Pujalte, D.; Petit, P.; Loubatieres-Mariani, M. M. Comparative effects of adenosine-5′- triphosphate and related analogs on insulin secretion from the rat pancreas Fundam. Clin. Pharmacol. 1997, 11, 537-545 (Pubitemid 27520917)
15. Farret, A.; Filhol, R.; Linck, N.; Manteghetti, M.; Vignon, J.; Gross, R.; Petit, P. P2Y receptor mediated modulation of insulin release by a novel generation of 2-substituted-5′-O-(1-boranotriphosphate)-adenosine analogues Pharm. Res. 2006, 23, 2665-2671 (Pubitemid 44691613)
16. Leon, C.; Freund, M.; Latchoumanin, O.; Farret, A.; Petit, P.; Cazenave, J.-P.; Gachet, C. The P2Y1 receptor is involved in the maintenance of glucose homeostasis and in insulin secretion in mice Purinergic Signalling 2005, 1, 145-151 (Pubitemid 40466900)
17. Nahum, V.; Zuendorf, G.; Levesque, S. A.; Beaudoin, A. R.; Reiser, G.; Fischer, B. Adenosine 5′-O-(1-boranotriphosphate) derivatives as novel P2Y1 receptor agonists J. Med. Chem. 2002, 45, 5384-5396 (Pubitemid 35429177)
18. 1 receptor agonists Eur. J. Med. Chem. 2009, 44, 1525-1536
19. Hoyle, C. H. V.; Hilderman, R. H.; Pintor, J. J.; Schluter, H.; King, B. F. Diadenosine polyphosphates as extracellular signal molecules Drug Dev. Res. 2001, 52, 260-273 (Pubitemid 32401948)
20. Fischer, B.; Boyer, J. L.; Hoyle, C. H. V.; Ziganshin, A. U.; Brizzolara, A. L.; Knight, G. E.; Zimmet, J.; Burnstock, G.; Harden, T. K.; Jacobson, K. A. Identification of potent, selective P2Y-purinoceptor agonists: structure-activity relationships for 2-thioether derivatives of adenosine 5′-triphosphate J. Med. Chem. 1993, 36, 3937-3946 (Pubitemid 24006724)
21. 1-receptor. 1. A synthetic, biochemical, and NMR approach J. Med. Chem. 1999, 42, 5325-5337 (Pubitemid 30036768)
22. Li, P.; Sergueeva, Z. A.; Dobrikov, M.; Shaw, B. R. Nucleoside and oligonucleoside boranophosphates: Chemistry and properties Chem. Rev. 2007, 107, 4746-4796 (Pubitemid 350237040)
23. Burgess, K.; Cook, D. Syntheses of nucleoside triphosphates Chem. Rev. 2000, 100, 2047-2059
24. Griffin, B. E.; Jarman, M.; Reese, C. B.; Sulston, J. E. The synthesis of oligoribonucleotides. II. Methoxymethylidene derivatives of ribonucleosides and 5′-ribonucleotides Tetrahedron 1967, 23, 2301-313
25. Major, D. T.; Nahum, V.; Wang, Y.; Reiser, G.; Fischer, B. Molecular recognition in purinergic receptors. 2. Diastereoselectivity of the h-P2Y1-receptor J. Med. Chem. 2004, 47, 4405-4416 (Pubitemid 39096829)
26. Li, P.; Shaw, B. R. Convenient synthesis of nucleoside borane diphosphate analogues: Deoxy- and ribonucleoside 5′-Pα-boranodiphosphates J. Org. Chem. 2004, 69, 7051-7057 (Pubitemid 39363000)
27. Krishnan, P.; Fu, Q.; Lam, W.; Liou, J.-Y.; Dutschman, G.; Cheng, Y.-C. Phosphorylation of pyrimidine deoxynucleoside analog diphosphates: Selective phosphorylation of L-nucleoside analog diphosphates by 3-phosphoglycerate kinase J. Biol. Chem. 2002, 277, 5453-5459 (Pubitemid 34968594)
28. Nahum, V.; Fischer, B. Boranophosphate salts as an excellent mimic of phosphate salts: Preparation, characterization, and properties Eur. J. Inorg. Chem. 2004, 4124-4131
29. Srivastava, P. C.; Robins, R. K.; Meyer, R. B., Jr. In Chemistry of nucleosides and nucleotides. Townsend, L. B., Ed.; Plenum Press: New York, 1988; Vol. 1.
30. Fujii, A.; Patwari, G. N.; Ebata, T.; Mikami, N. Vibrational spectroscopic evidence of unconventional hydrogen bonds Int. J. Mass Spectrom. 2002, 220, 289-312
31. Zatorski, A.; Goldstein, B. M.; Colby, T. D.; Jones, J. P.; Pankiewicz, K. W. Potent inhibitors of human inosine monophosphate dehydrogenase type II. Fluorine-substituted analogs of thiazole-4-carboxamide adenine dinucleotide J. Med. Chem. 1995, 38, 1098-1105
32. Parr, C. E.; Sullivan, D. M.; Paradiso, A. M.; Lazarowski, E. R.; Burch, L. H.; Olsen, J. C.; Erb, L.; Weisman, G. A.; Boucher, R. C.; Turner, J. T. Cloning and expression of a human P2U nucleotide receptor, a target for cystic fibrosis pharmacotherapy Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 3275-3279
33. Schachter, J. B.; Li, Q.; Boyer, J. L.; Nicholas, R. A.; Harden, T. K. Second messenger cascade specificity and pharmacological selectivity of the human P2Y1-purinoceptor Br. J. Pharmacol. 1996, 118, 167-173
34. Yelovitch, S.; Camden, J.; Weisman, G. A.; Fischer, B. Boranophosphate isoster controls P2Y receptor subtype selectivity and metabolic stability of dinucleoside polyphosphate analogues J. Med. Chem. 2012, 55, 437-448
35. Moss, D. W.; Walli, A. K. Intermediates in the hydrolysis of ATP by human alkaline phosphatase Biochim. Biophys. Acta, Enzymol. 1969, 191, 476-477
36. Harada, M.; Udagawa, N.; Fukasawa, K.; Hiraoka, B. Y.; Mogi, M. Inorganic pyrophosphatase activity of purified bovine pulp alkaline phosphatase at physiological pH J. Dent. Res. 1986, 65, 125-127
37. Belli, S. I.; Goding, J. W. Biochemical characterization of human PC-1, an enzyme possessing alkaline phosphodiesterase I and nucleotide pyrophosphatase activities Eur. J. Biochem. 1994, 226, 433-443 (Pubitemid 24379062)
38. Gendaszewska-Darmach, E.; Maszewska, M.; Zaklos, M.; Koziolkiewicz, M. Degradation of extracellular nucleotides and their analogs in HeLa and HUVEC cell cultures Acta Biochim. Pol. 2003, 50, 973-984 (Pubitemid 38608831)
39. Eliahu, S.; Barr, H. M.; Camden, J.; Weisman, G. A.; Fischer, B. A novel insulin secretagogue based on a dinucleoside polyphosphate scaffold(1) J. Med. Chem. 2010, 53, 2472-2481
40. Lenzen, S. The mechanisms of alloxan- and streptozotocin-induced diabetes Diabetologia 2008, 51, 216-226
41. Chung, W. K.; Belfi, K.; Chua, M.; Wiley, J.; Mackintosh, R.; Nicolson, M.; Boozer, C. N.; Leibel, R. L. Heterozygosity for Lepob or Leprdb affects body composition and leptin homeostasis in adult mice Am. J. Physiol. 1998, 274, R985-R990
42. Boarder, M. R.; Webb, T. P2Y receptors: structure and function. In Purinergic and Pyrimidinergic Signalling; Abbracchio, M. P.; Williams, M., Eds.; Handbook of Experimental Pharmacology, Springer Verlag: Heidelberg, 2001; Vol. 151, Part 1, pp 65-88.
43. Jin, J.; Daniel, J. L.; Kunapuli, S. P. Molecular basis for ADP-induced platelet activation J. Biol. Chem. 1998, 273, 2030-2034
44. Cattaneo, M. New P2Y(12) inhibitors Circulation 2010, 121, 171-179
45. Ferreira, Z. S.; Silva, C. L. M. Comparative aspects of purinergic receptors in the phylogenetic scale; Research Signpost: Kerala, India, 2009; pp 73-91.
46. Shaver, S. R.; Rideout, J. L.; Pendergast, W.; Douglass, J. G.; Brown, E. G.; Boyer, J. L.; Patel, R. I.; Redick, C. C.; Jones, A. C.; Picher, M.; Yerxa, B. R. Structure-activity relationships of dinucleotides: Potent and selective agonists of P2Y receptors Purinergic Signalling 2005, 1, 183-191 (Pubitemid 40466903)
47. 32P]diphosphate: Synthesis and use as probe of platelet ADP receptors Methods Enzymol. 1992, 215, 137-142
48. Kikugawa, K.; Suehiro, H.; Ichino, M. Platelet aggregation inhibitors. 6. 2-Thioadenosine derivatives J. Med. Chem. 1973, 16, 1381-1388
49. Li, P.; Xu, Z.; Liu, H.; Wennefors, C. K.; Dobrikov, M. I.; Ludwig, J.; Shaw, B. R. Synthesis of a-P-modified nucleoside diphosphates with ethylenediamine J. Am. Chem. Soc. 2005, 127, 16782-16783 (Pubitemid 41772827)
50. 2 nucleotide receptor. Consequences of truncation of the C terminus J. Biol. Chem. 1998, 273, 29437-29444 (Pubitemid 28509947)
51. Brandenberger, H.; Hanson, R. Spectrophotometric determination of acid and alkaline phosphatases Helv. Chim. Acta 1953, 36, 900-906
52. Cattaneo, M. Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function Semin. Thromb. Hemostasis 2009, 35, 158-167
53. Jakubowski, J. A.; Winters, K. J.; Naganuma, H.; Wallentin, L. Prasugrel: A novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile Cardiovasc. Drug Rev. 2007, 25, 357-374 (Pubitemid 350233359)